One of the key drivers of the market is the increasing awareness of UTIs. With the growing availability of information online and through social media, more and more people are becoming aware of the symptoms of UTIs and the importance of seeking prompt treatment. This is leading to higher demand for antibiotics and other treatments, driving growth in the market.
Seize Excellence Today: Claim Your Sample for Unmatched Efficiency:
Another factor driving the market is the growing geriatric population. As people age, their risk of developing UTIs increases, and with the world’s population aging rapidly, the demand for UTI treatments is also increasing. According to the United Nations, the number of people aged 65 and over is expected to triple by 2050, reaching nearly 1.5 billion.
Finally, the rising incidence of UTIs is also contributing to the growth of the market. Factors such as the growing prevalence of diabetes, changes in sexual behavior, and the increasing use of catheters and other medical devices are all leading to higher rates of UTIs. This is creating a growing demand for effective treatments that can quickly and safely clear up UTIs.
The global Uncomplicated urinary tract infection treatment market is expected to grow with a 10% CAGR during 2023 to 2033. Retail pharmacies are expected to hold 47% of the market share in 2023 for Uncomplicated urinary tract infection treatment market. North America is expected to possess 48% market share for Uncomplicated urinary tract infection treatment market in 2023. Europe uncomplicated urinary tract infection treatment market size is expected to possess 40% market share in 2023. Retail Pharmacies Expected to Procure 47% Market Share for Uncomplicated Urinary Tract Infection Treatment Market: FMI Study
Key players are investing heavily in research and development to bring new and improved treatments to market, and are also working to expand their distribution networks to reach more patients.” states an FMI analyst
Competitive Landscape :
Key players in the uncomplicated urinary tract infection treatment market are GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, Fimbrion Therapeutics, Pfizer, Allergan Plc, Bristol-Myers Squibb, Merck Co., Inc., Cipla Inc.
GSK has developed a drug called Avycaz, which is a combination of ceftazidime and avibactam, used for the treatment of complicated UTIs. Avycaz is effective against a wide range of gram-negative bacteria, including some that are resistant to other antibiotics. Iterum Therapeutics is a biopharmaceutical company that is focusing on developing novel antibiotics to treat infections caused by multi-drug resistant pathogens, including those that cause Uncomplicated Urinary Tract Infections (UTIs).
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Uncomplicated urinary tract infection treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights based on Drug Class (Gepotidacin, Probenecid, Sulfonamide, Tetracycline, Nitrofuran) Distribution Channel (Hospital Pharmacies, Gynaecology and Urology Clinics, Retail Pharmacies, Online Drug Stores) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East Africa)
Key Segments Profiled in the Uncomplicated Urinary Tract Infection Treatment Industry Survey
Gepotidacin Probenecid Sulfonamide Tetracycline Nitrofuran
Hospital Pharmacies Gynaecology and Urology Clinics Retail Pharmacies Online Drug Stores